This is a routine proxy solicitation with no new financial or operational information. Monitor the meeting outcome for any unexpected dissent, but no immediate trading catalyst is present.
Price Chart
Executive Summary
RedHill Biopharma filed a 6-K containing the notice and proxy statement for its annual general meeting on July 28, 2026. The agenda includes routine items: re-appointment of auditors, re-election of two directors, and approval of the CEO/Chairman's continued service. No material financial or operational updates are provided.
Key Facts
- Annual general meeting scheduled for July 28, 2026.
- Proposals: re-appoint PwC Israel as auditors, re-elect directors Rick D. Scruggs and Dr. Shmuel Cabilly, and approve CEO/Chairman Dror Ben-Asher's engagement for three more years.
- Record date for voting: June 23, 2026; 60,809,201,000 ordinary shares outstanding (represented by 6,080,920 ADSs).
- Board recommends a 'FOR' vote on all proposals.
Financial Impact
No financial impact from this routine proxy filing.
Risk Factors
- No material risks identified from this filing; however, the company's prior 20-F highlighted going-concern uncertainty and Nasdaq delisting risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-003333 |
| Document: 0001178913-26-003333-index-headers.html | 0001178913-26-003333 |
| Document: 0001178913-26-003333-index.html | 0001178913-26-003333 |
| Document: 0001178913-26-003333.txt | 0001178913-26-003333 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.4550 | awaiting T+60 | — | $0.4159 (−8.59%) |
Oct 19, 2026 7d ago | 6-K | $0.5012 | awaiting T+60 | — | $0.4159 (−17.02%) |
Oct 19, 2026 7d ago | Press Release | $0.5012 | awaiting T+60 | — | $0.4159 (−17.02%) |
Oct 13, 2026 13d ago | 6-K | $0.4862 | awaiting T+60 | — | $0.4159 (+14.46%) |
Oct 13, 2026 13d ago | 424B5 | $0.4862 | awaiting T+60 | — | $0.4159 (+14.46%) |
Oct 7, 2026 19d ago | 6-K | $0.4740 | awaiting T+60 | — | $0.4159 (−12.26%) |
Sep 1, 2026 7w ago | 6-K | $0.8700 | awaiting T+60 | — | $0.4159 (−52.20%) |
Aug 31, 2026 8w ago | 6-K | $0.9000 | awaiting T+60 | — | $0.4159 (−53.79%) |
Aug 7, 2026 11w ago | 6-K | $0.6050 | awaiting T+60 | — | $0.4159 (−31.26%) |
Aug 6, 2026 11w ago | 6-K | $0.5810 | awaiting T+60 | — | $0.4159 (−28.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers